CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

NASDAQ:CPRX • US14888U1016

24.88 USD
+0.02 (+0.08%)
At close: Feb 26, 2026
24.39 USD
-0.49 (-1.97%)
Pre-Market: 2/27/2026, 8:52:51 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to CPRX. CPRX was compared to 521 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on CPRX. These ratings would make CPRX suitable for value investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year CPRX was profitable.
  • In the past year CPRX had a positive cash flow from operations.
  • CPRX had positive earnings in 4 of the past 5 years.
  • CPRX had a positive operating cash flow in 4 of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 20.69%, CPRX belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 23.65%, CPRX belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
  • The Return On Invested Capital of CPRX (21.23%) is better than 97.89% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.14%.
  • The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROIC 21.23%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.93% of its industry peers.
  • In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
  • The Operating Margin of CPRX (44.78%) is better than 99.23% of its industry peers.
  • In the last couple of years the Operating Margin of CPRX has grown nicely.
  • CPRX has a better Gross Margin (85.68%) than 88.29% of its industry peers.
  • CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CPRX is creating value.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • CPRX has an Altman-Z score of 16.75. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
  • CPRX has a Altman-Z score of 16.75. This is amongst the best in the industry. CPRX outperforms 87.14% of its industry peers.
  • There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.75
ROIC/WACC2.44
WACC8.69%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.62, CPRX is doing good in the industry, outperforming 67.37% of the companies in the same industry.
  • CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
  • CPRX's Quick ratio of 6.40 is fine compared to the rest of the industry. CPRX outperforms 65.83% of its industry peers.
Industry RankSector Rank
Current Ratio 6.62
Quick Ratio 6.4
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.62% over the past year.
  • The Earnings Per Share has been growing by 36.74% on average over the past years. This is a very strong growth
EPS 1Y (TTM)49.62%
EPS 3Y38.36%
EPS 5Y36.74%
EPS Q2Q%54.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%

3.2 Future

  • Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.75% on average per year.
  • CPRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.54% yearly.
EPS Next Y-7.37%
EPS Next 2Y-2.41%
EPS Next 3Y23.39%
EPS Next 5Y21.75%
Revenue Next Year6.96%
Revenue Next 2Y7.32%
Revenue Next 3Y8.6%
Revenue Next 5Y7.54%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 12.69, which indicates a correct valuation of CPRX.
  • Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.35% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.11, CPRX is valued rather cheaply.
  • A Price/Forward Earnings ratio of 13.70 indicates a correct valuation of CPRX.
  • CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.55% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, CPRX is valued rather cheaply.
Industry RankSector Rank
PE 12.69
Fwd PE 13.7
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 98.08% of the companies in the same industry.
  • CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.03
EV/EBITDA 7.98
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
  • CPRX's earnings are expected to grow with 23.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-2.41%
EPS Next 3Y23.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (2/26/2026, 8:19:16 PM)

Premarket: 24.39 -0.49 (-1.97%)

24.88

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners86.97%
Inst Owner Change-0.77%
Ins Owners5.48%
Ins Owner Change2.86%
Market Cap3.06B
Revenue(TTM)N/A
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (41.44%)
Short Float %7.67%
Short Ratio7.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)0.21%
PT rev (3m)1.47%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)17.48%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.91%
Valuation
Industry RankSector Rank
PE 12.69
Fwd PE 13.7
P/S 5.29
P/FCF 13.03
P/OCF 13.03
P/B 3.32
P/tB 3.86
EV/EBITDA 7.98
EPS(TTM)1.96
EY7.88%
EPS(NY)1.82
Fwd EY7.3%
FCF(TTM)1.91
FCFY7.67%
OCF(TTM)1.91
OCFY7.68%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)N/A
PEG (5Y)0.35
Graham Number18.17
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROCE 28.06%
ROIC 21.23%
ROICexc 84.1%
ROICexgc 187.79%
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
FCFM 40.59%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.31%
Cap/Sales 0.02%
Interest Coverage 593.88
Cash Conversion 79.12%
Profit Quality 107.83%
Current Ratio 6.62
Quick Ratio 6.4
Altman-Z 16.75
F-Score6
WACC8.69%
ROIC/WACC2.44
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)49.62%
EPS 3Y38.36%
EPS 5Y36.74%
EPS Q2Q%54.55%
EPS Next Y-7.37%
EPS Next 2Y-2.41%
EPS Next 3Y23.39%
EPS Next 5Y21.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%
Revenue Next Year6.96%
Revenue Next 2Y7.32%
Revenue Next 3Y8.6%
Revenue Next 5Y7.54%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%

CATALYST PHARMACEUTICALS INC / CPRX FAQ

What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPRX.


What is the valuation status for CPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.


Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.


What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?

The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to decline by -7.37% in the next year.